Arterial Spin-Labeling Assessment of Normalized Vascular Intratumoral Signal Intensity as a Predictor of Histologic Grade of Astrocytic Neoplasms

REFERENCES

1. 1.↵
   1. Wöhrer A,
   2. Waldhör T,
   3. Heinzl H,
   4. et al

   . The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J NeuroOncol 2009;95:401–11

   CrossRefPubMed
2. 2.↵
   1. Surawicz TS,
   2. McCarthy BJ,
   3. Kupelian V,
   4. et al

   . Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. NeuroOncol 1999;1:14–25

   Abstract/FREE Full Text
3. 3.↵
   1. Pope WB,
   2. Sayre J,
   3. Perlina A,
   4. et al

   . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466–74

   Abstract/FREE Full Text
4. 4.↵
   1. Daumas-Duport C,
   2. Scheithauer B,
   3. O'Fallon J,
   4. et al

   . Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62:2152–65

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Knopp E,
   2. Cha S,
   3. Johnson G,
   4. et al

   . Glial neoplasms: dynamic contrast-enhanced T2*-weighed MR imaging. Radiology 1999;211:791–98

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Law M,
   2. Yang S,
   3. Babb JS,
   4. et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

   Abstract/FREE Full Text
7. 7.↵
   1. Hu LS,
   2. Baxter LC,
   3. Pinnaduwage DS,
   4. et al

   . Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31:40–48

   Abstract/FREE Full Text
8. 8.↵
   1. Golay X,
   2. Petersen E

   . Arterial spin labeling: benefits and pitfalls of high magnetic field. Neuroimaging Clin North Am 2006;16:259–68

   CrossRef
9. 9.↵
   1. Chen Y,
   2. Wang DJJ,
   3. Detre JA

   . Test-retest reliability of arterial spin labeling with common labeling strategies. J Magn Reson Imaging 2011;33:940–49

   CrossRefPubMed
10. 10.↵
    1. Järnum H,
    2. Steffensen EG,
    3. Knutsson L,
    4. et al

    . Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging. Neuroradiology 2010;52:307–17

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Warmuth C,
    2. Gunther M,
    3. Zimmer C

    . Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Weber M-A,
    2. Günther M,
    3. Lichy MP,
    4. et al

    . Comparison of arterial spin-labeling techniques and dynamic susceptibility-weighted contrast-enhanced MRI in perfusion imaging of normal brain tissue. Invest Radiol 2003;38:712–18

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Hirai T,
    2. Kitajima M,
    3. Nakamura H,
    4. et al

    . Quantitative blood flow measurements in gliomas using arterial spin-labeling at 3T: intermodality agreement and inter- and intraobserver reproducibility study. AJNR Am J Neuroradiol 2011;32:2073–79

    Abstract/FREE Full Text
14. 14.↵
    1. Koziak AM,
    2. Winter J,
    3. Lee T-Y,
    4. et al

    . Validation study of a pulsed arterial spin labeling technique by comparison to perfusion computed tomography. Magn Reson Imaging 2008;26:543–53

    CrossRefPubMed
15. 15.↵
    1. Weber M-A,
    2. Henze M,
    3. Tüttenberg J,
    4. et al

    . Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol 2010;45:755–68

    CrossRefPubMed
16. 16.↵
    1. Deibler AR,
    2. Pollock JM,
    3. Kraft RA,
    4. et al

    . Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts. AJNR Am J Neuroradiol 2008;29:1228–34

    Abstract/FREE Full Text
17. 17.↵
    1. Lu H,
    2. Clingman C,
    3. Golay X,
    4. et al

    . Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla. Magn Reson Med 2004;52:679–82

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Kim MJ,
    2. Kim HS,
    3. Kim J-H,
    4. et al

    . Diagnostic accuracy and interobserver variability of pulsed arterial spin labeling for glioma grading. Acta Radiol 2008;49:450–57

    FREE Full Text
19. 19.↵
    1. Lev MH,
    2. Ozsunar Y,
    3. Henson JW,
    4. et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
20. 20.↵
    1. Wong EC,
    2. Buxton RB,
    3. Frank LR

    . Implementation of quantitative perfusion imaging techniques for functional brain mapping using pulsed arterial spin labeling. NMR Biomed 1997;10:237–49

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Wen PY,
    2. Macdonald DR,
    3. Reardon DA,
    4. et al

    . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72

    Abstract/FREE Full Text
22. 22.↵
    1. Hendrikse J,
    2. Van Osch M,
    3. Rutgers D,
    4. et al

    . Internal carotid artery occlusion assessed at pulsed arterial spin-labeling perfusion MR imaging at multiple delay times. Radiology 2004;233:899–904

    CrossRefPubMed
23. 23.↵
    1. MacIntosh BJ,
    2. Filippini N,
    3. Chappell MA,
    4. et al

    . Assessment of arterial arrival times derived from multiple inversion time pulsed arterial spin labeling MRI. Magn Reson Med 2010;63:641–47

    CrossRefPubMed
24. 24.↵
    1. Chawla S,
    2. Wang S,
    3. Wolf RL,
    4. et al

    . Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683–89

    Abstract/FREE Full Text
25. 25.↵
    1. Liu P,
    2. Uh J,
    3. Lu H

    . Determination of spin compartment in arterial spin labeling MRI. Magn Reson Med 2011;65:120–27

    CrossRefPubMed
26. 26.↵
    1. Wolf RL,
    2. Wang J,
    3. Wang S,
    4. et al

    . Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 2005;22:475–82

    CrossRefPubMed
27. 27.↵
    1. Barker FG,
    2. Chang SM,
    3. Huhn SL,
    4. et al

    . Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936–41

    CrossRefPubMed
28. 28.↵
    1. Law M,
    2. Yang S,
    3. Wang H,
    4. et al

    . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
29. 29.↵
    1. Friedman HS,
    2. Prados MD,
    3. Wen PY,
    4. et al

    . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40

    Abstract/FREE Full Text
30. 30.↵
    1. Vredenburgh JJ,
    2. Desjardins A,
    3. Herndon JE,
    4. et al

    . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–29

    Abstract/FREE Full Text